Companies: 10,795·Total market cap: $144.5T
Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

ALDXNASDAQHealthcare● Active
$1.78
+$0.15(+8.90%)
Market Cap$107069896
P/E Ratio
52W High$6.175
52W Low$1.07
SEC Filings

Aldeyra Therapeutics, Inc. (ALDX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001341235 · ALDX · NASDAQ · as of Jun 8, 2026

Filing snapshot

631
Total Filings
4
Latest Form
2026-06-05
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001341235 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-27
Fiscal Year End
Feb 27, 2026
Accession No.
0001193125-26-083012
Primary Document
aldx-20251231.htm
Source: data.sec.gov · CIK 0001341235 · Accession 0001193125-26-083012

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-01Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-01
View
ARSARS
ARS
2026-04-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-27
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-20
View
8-KCurrent Report
8-K
2026-04-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
8-KCurrent Report
8-K
2026-03-17
View
S-8Employee Stock Plan Registration
S-8
2026-02-27
View
10-KAnnual Report
10-K
2026-02-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
8-KCurrent Report
8-K
2025-12-31
View
8-KCurrent Report
8-K
2025-12-16
View
Showing 1–15 of 434 filingsForm 4 / 144 hidden· 631 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001341235  |  Exchange: NASDAQ · Healthcare

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has submitted 631 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001341235, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aldeyra Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Aldeyra Therapeutics, Inc. 10-K was filed on 2026-02-27 for fiscal year ending 2026. Historical ALDX 10-K annual reports are available from 2005 through 2026.

Investors researching Aldeyra Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ALDX SEC Filings · 8 questions

Aldeyra Therapeutics, Inc. (ALDX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 631 filings and access original documents at no cost. Aldeyra Therapeutics, Inc.'s CIK is 0001341235.

ALDX SEC filingsAldeyra Therapeutics, Inc. SEC documentsfind ALDX 10-K